Search - tctmd.com

Displaying 1 - 20 of 46

Sort: Relevancy | Date

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

News Conference News SCAI 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

May 10, 2024

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

News Daily News

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

October 16, 2023

FDA Approves DETOUR for Percutaneous Bypass in Long, Complex SFA

News Conference News LINC 2023

FDA Approves DETOUR for Percutaneous Bypass in Long, Complex SFA

June 08, 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

January 20, 2023

MOSAIC: Home Intervention Boosts Walking Time in PAD Patients

News Daily News

MOSAIC: Home Intervention Boosts Walking Time in PAD Patients

April 15, 2022

Medtronic Recalls TurboHawk Plus Atherectomy System

News Daily News

Medtronic Recalls TurboHawk Plus Atherectomy System

March 09, 2022

Class I Recall for Cordis’ Super Torque Catheters with Radiopaque Markers

News Daily News

Class I Recall for Cordis’ Super Torque Catheters with Radiopaque Markers

Michael O'Riordan

September 23, 2021

The finding, from a study with a mean follow-up of 2-and-a-half years, bolsters support for trials and device use to continue.

News Daily News

SWEDEPAD: No Mortality Signal With Paclitaxel in PAD

December 18, 2020

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

January 24, 2020

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

News Daily News

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

August 07, 2019

TCTMD’s Top 10 Most Popular Stories for June 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2019

June 28, 2019

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

June 19, 2019

US Data Convey the Scope of Bleeding in Lower-Extremity Peripheral Interventions

News Daily News

US Data Convey the Scope of Bleeding in Lower-Extremity Peripheral Interventions

June 18, 2019

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

June 10, 2019

Supervised Exercise Plus Angioplasty Best for Intermittent Claudication: Meta-analysis

News Daily News

Supervised Exercise Plus Angioplasty Best for Intermittent Claudication: Meta-analysis

June 03, 2019

Peripheral Vision: As Office-Based Practices Proliferate, Who Is Watching Out for Patients?

News Features

Peripheral Vision: As Office-Based Practices Proliferate, Who Is Watching Out for Patients?

May 01, 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

March 06, 2019

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

March 01, 2019

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

January 25, 2019

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

November 13, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.